Antibodies to granulocyte-macrophage colony-stimulating factor
View Patent ↗The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
1. An isolated anti-GM-CSF antibody, comprising:
a V H that has a CDR1 having a sequence NYYIH (SEQ ID NO:25), a CDR2 having a sequence WINAGNGNTKYSQKFQG (SEQ ID NO:27), and a CDR3 having a sequence RQRFPYYFDY (SEQ ID NO:16); and
a V L that has a CDR1 having a sequence RASQSVGTNVA (SEQ ID NO:31), a CDR2 having a sequence STSSRAT (SEQ ID NO:33), and a CDR3 having a sequence QQFNKSPLT (SEQ ID NO:18).
2. A pharmaceutical composition comprising the isolated anti-GM-CSF antibody of claim 1 and a physiologically acceptable carrier.
3. An isolated anti-GM-CSF antibody, comprising:
a VH having a sequence of VH#5 (SEQ ID NO:5);
a VL region having a sequence of VK#2 (SEQ ID NO:7);
a heavy chain constant region having the amino acid sequence set forth in SEQ ID NO: 11; and
a kappa light chain constant region having the amino acid sequence set forth in SEQ ID NO:10.
4. A pharmaceutical composition comprising the isolated anti-GM-CSF antibody of claim 3 and a physiologically acceptable carrier.